506 related articles for article (PubMed ID: 16265687)
1. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
[TBL] [Abstract][Full Text] [Related]
2. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
Emery P; Fleischmann R; Filipowicz-Sosnowska A; Schechtman J; Szczepanski L; Kavanaugh A; Racewicz AJ; van Vollenhoven RF; Li NF; Agarwal S; Hessey EW; Shaw TM;
Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
Keystone E; Fleischmann R; Emery P; Furst DE; van Vollenhoven R; Bathon J; Dougados M; Baldassare A; Ferraccioli G; Chubick A; Udell J; Cravets MW; Agarwal S; Cooper S; Magrini F
Arthritis Rheum; 2007 Dec; 56(12):3896-908. PubMed ID: 18050221
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial.
Mease PJ; Cohen S; Gaylis NB; Chubick A; Kaell AT; Greenwald M; Agarwal S; Yin M; Kelman A
J Rheumatol; 2010 May; 37(5):917-27. PubMed ID: 20194448
[TBL] [Abstract][Full Text] [Related]
6. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
Mease PJ; Revicki DA; Szechinski J; Greenwald M; Kivitz A; Barile-Fabris L; Kalsi J; Eames J; Leirisalo-Repo M
J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.
Gerloni V; Pontikaki I; Gattinara M; Desiati F; Lupi E; Lurati A; Salmaso A; Fantini F
Arthritis Rheum; 2005 Feb; 52(2):548-53. PubMed ID: 15693004
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
9. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs.
Popa C; Leandro MJ; Cambridge G; Edwards JC
Rheumatology (Oxford); 2007 Apr; 46(4):626-30. PubMed ID: 17189244
[TBL] [Abstract][Full Text] [Related]
10. Rituximab therapy in rheumatoid arthritis in daily practice.
Assous N; Gossec L; Dieudé P; Meyer O; Dougados M; Kahan A; Allanore Y
J Rheumatol; 2008 Jan; 35(1):31-4. PubMed ID: 18176989
[TBL] [Abstract][Full Text] [Related]
11. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
Edwards JC; Szczepanski L; Szechinski J; Filipowicz-Sosnowska A; Emery P; Close DR; Stevens RM; Shaw T
N Engl J Med; 2004 Jun; 350(25):2572-81. PubMed ID: 15201414
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells.
De Vita S; Zaja F; Sacco S; De Candia A; Fanin R; Ferraccioli G
Arthritis Rheum; 2002 Aug; 46(8):2029-33. PubMed ID: 12209504
[TBL] [Abstract][Full Text] [Related]
14. Adsorptive granulocyte/monocyte apheresis for the treatment of refractory rheumatoid arthritis: an open pilot multicentre trial.
Sanmartí R; Marsal S; Valverde J; Casado E; Lafuente R; Kashiwagi N; Rodriguez-Cros JR; Erra A; Reina D; Gratacós J
Rheumatology (Oxford); 2005 Sep; 44(9):1140-4. PubMed ID: 15927997
[TBL] [Abstract][Full Text] [Related]
15. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
Rau R; Sander O; van Riel P; van de Putte L; Hasler F; Zaug M; Kneer J; van der Auwera P; Stevens RM;
J Rheumatol; 2003 Apr; 30(4):680-90. PubMed ID: 12672184
[TBL] [Abstract][Full Text] [Related]
16. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.
Genovese MC; Kaine JL; Lowenstein MB; Del Giudice J; Baldassare A; Schechtman J; Fudman E; Kohen M; Gujrathi S; Trapp RG; Sweiss NJ; Spaniolo G; Dummer W;
Arthritis Rheum; 2008 Sep; 58(9):2652-61. PubMed ID: 18759293
[TBL] [Abstract][Full Text] [Related]
17. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
Valleala H; Korpela M; Möttönen T; Hienonen-Kempas T; Kauppi M; Hannonen P; Leirisalo-Repo M
Scand J Rheumatol; 2009; 38(5):323-7. PubMed ID: 19585384
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for the treatment of rheumatoid arthritis.
Schuna AA
Pharmacotherapy; 2007 Dec; 27(12):1702-10. PubMed ID: 18041890
[TBL] [Abstract][Full Text] [Related]
19. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response.
Breedveld F; Agarwal S; Yin M; Ren S; Li NF; Shaw TM; Davies BE
J Clin Pharmacol; 2007 Sep; 47(9):1119-28. PubMed ID: 17766699
[TBL] [Abstract][Full Text] [Related]
20. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy.
Gonzalez-Juanatey C; Llorca J; Vazquez-Rodriguez TR; Diaz-Varela N; Garcia-Quiroga H; Gonzalez-Gay MA
Arthritis Rheum; 2008 Dec; 59(12):1821-4. PubMed ID: 19035415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
